Inceptor Bio will use proceeds from a $37 million series A round to push its lead CAR-T program into phase 1 trials in 2023 and set up manufacturing capability in Florida. Research Triangle Park, ...

RALEIGH, N.C., June 14, 2021 /PRNewswire/ -- Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotech, announced today that it is developing multiple next-generation ...

RALEIGH, N.C., Dec. 16, 2021 /PRNewswire/ -- Inceptor Bio, a Research Triangle Park-based next-generation cell and gene therapy biotechnology company, today announced that it has executed an ...

Prof. Heiko Lickert is the director of the Institute of Diabetes and Regeneration Research at Helmholtz Munich, professor at the Technical University of Munich (TUM), and member of the German Center ...

CAR-Ts have already changed the treatment landscape when it comes to blood cancers, but getting a cell therapy to market for solid tumors remains tantalizingly out of reach. Now, Inceptor Bio and cell ...

Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development. On June 30, 2022, Inceptor Bio, a US-based biotechnology company ...

RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2025 /PRNewswire/ -- Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has ...

Three years ago, the inceptor protein was discovered and its role as an inhibitor of the insulin signaling pathway was described. Inceptor and the insulin receptor are located on the surface of beta ...

Inceptor Bio, a recently founded biotechnology company searching for cancer treatments, says it has raised $26 million from investors and is on the hunt for manufacturing space in the Triangle. The ...

Research targeting the insulin-inhibitory receptor, called inceptor, unveils promising avenues for beta cell protection, offering hope for causal diabetes therapy. A novel study in mice with ...